rebel Financial rebel Financial
← All Posts

Sanofi

April 24, 2026 • Author: Phil Ratcliff
Item Proposal Vote
1 Approval of the individual company financial statements for the year ended December 31, 2025 ✓ For
2 Approval of the consolidated financial statements for the year ended December 31, 2025 ✓ For
3 Appropriation of profits for the year ended December 31, 2025 and declaration of dividend ✓ For
4 Reappointment of Christophe Babule as a director ✗ Against
5 Reappointment of Jean-Paul Kress as a director ✓ For
6 Appointment of Belén Garijo as a director ✗ Against
7 Appointment of Christel Heydemann as a director ✓ For
8 Approval of the report on the compensation of corporate officers issued in accordance with Article L. 22-10-9 of the French Commercial Code ✓ For
9 Approval of the components of the compensation paid or awarded in respect of the year ended December 31, 2025 to Frédéric Oudéa, Chairman of the Board ✓ For
10 Approval of the components of the compensation paid or awarded in respect of the year ended December 31, 2025 to Paul Hudson, Chief Executive Officer ✓ For
11 Setting of the amount of directors’ compensation ✓ For
12 Approval of the compensation policy for directors ✓ For
13 Approval of the compensation policy for the Chairman of the Board of Directors ✓ For
14 Approval of the compensation policy for Paul Hudson, Chief Executive Officer until end-of-day on February 17, 2026 ✓ For
15 Approval of the compensation policy for Olivier Charmeil, Interim Chief Executive Officer ✓ For
16 Approval of the compensation policy for Belén Garijo, future Chief Executive Officer ✓ For
17 Authorization to the Board of Directors to carry out transactions in the Company’s shares (usable outside the period of a public tender offer) ✓ For
18 Amendment to the Company’s Articles of Association ✓ For
19 Delegation to the Board of Directors of competence to decide on the issuance of shares or securities giving access to the Company’s share capital reserved for members of savings plans, with waiver of preemptive rights in their favor ✓ For
20 Delegation to the Board of Directors of competence to decide on the issuance of shares or securities giving access to the Company’s share capital to categories of beneficiaries consisting of employees and corporate officers of foreign subsidiaries, with waiver of preemptive rights in their favor ✓ For
21 Powers to carry out formalities ✓ For
Attachments
📄
Sanofi_Annual_Report.pdf 11.2 MB
📄
Sanofi_proposed_resolutions.pdf 0.3 MB
This article was written for information purposes only and its content should not be construed by any consumer and/or prospective client as rebel Financial's solicitation to affect, or attempt to affect transactions in securities, or the rendering of personalized investment advice for compensation. No client or prospective client should assume that any such discussion serves as the receipt of, or a substitute for, personalized advice from rebel Financial, or from any other investment professional. See our disclosures page for more information.